Mural Oncology plc

Mural Oncology — Investor Presentation (March 2025)

35 slides from Mural Oncology's investor presentation, Mar 11, 2025

  1. Slide 1: Investor Presentation March 2025

    INVESTOR PRESENTATION March 2025 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements set forth in this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words “anticipate,” “believe,” “expect,” “may,” “will” and similar expressions are intended

  3. Slide 3: Section 1: Executive Summary

    Section 1: Executive Summary

  4. Slide 4: Mural Oncology: Building a New Class of Cytokine Therapies

    Mural Oncology: Building a New Class of Cytokine Therapies Abbrev.: CM: cutaneous melanoma; IL-12: interleukin-12; IL-18: interleukin-18; MM: mucosal melanoma; OS: overall survival; PDR: preliminary data readout; PROC: platinum resistant ovarian cancer; RP2D: recommended phase 2 dose; TLR: topline r

  5. Slide 5: Highly Experienced Late-Stage Oncology Team

    Highly Experienced Late-Stage Oncology Team Executive Team Caroline Loew, PhD CEO Vicki Goodman, MD CMO Maiken Keson-Brookes CLO Adam Cutler CFO Board of Directors Francis Cuss MB, BChir, FRCP Scott Jackson MBA – Chairman Caroline Loew PhD George Golumbeski PhD Sachiyo Minegishi MBA Benjamin Hickey

  6. Slide 6: Pipeline Overview: 2024-2026 Milestones

    Pipeline Overview: 2024-2026 Milestones Discovery Preclinical Phase 1 Phase 2 Phase 3 Indication Dosing Nemvaleukin (IV) Combination with Pembrolizumab (Potentially Registrational) Platinum Resistant Ovarian Cancer (PROC) (ARTISTRY-7) Nemvaleukin (IV) Monotherapy (Potentially Registrational) Mucosal

  7. Slide 7: Section 2: Nemvaleukin ALFA

    Section 2: Nemvaleukin ALFA

  8. Slide 8: Nemvaleukin: Engineered to Unlock the Efficacy Potential of the IL-2 Pathway

    Nemvaleukin: Engineered to Unlock the Efficacy Potential of the IL-2 Pathway for More Patients PROLEUKIN©(aldesleukin): proven curative potential in melanoma and RCC Extremely durable complete responses Toxic AE profile requires administration in an acute care setting, severely limits use to the fit

  9. Slide 9: Nemvaleukin's Design Differentiates It from Other IL-2 Pathway Approaches

    Nemvaleukin’s Design Differentiates It from Other IL-2 Pathway Approaches with the Potential to be First-in-Class Nemvaleukin Abbrev: CPI: checkpoint inhibitor; IL-2: interleukin-2 Other IL-2 Variant Approaches: Shielding Prodrug Require activation upon dosing Degrade to native IL-2 Include non-nati

  10. Slide 10: ARTISTRY-1: First-In-Human Trial of IV Nemvaleukin

    ARTISTRY-1: First-In-Human Trial of IV Nemvaleukin Global, Multicenter, Open-Label Phase 1/2 Trial Dose Expansion NCTO2799095 1. Patients from Parts A and B could roll over to Part C upon progression or stable disease (after > 4 cycles) on monotherapy 2. Nemvaleukin daily Q5D, then off treatment for

  11. Slide 11: ARTISTRY-1 Proof of Mechanism: Preferentially Expands CD8+ T Cells and NK Cells

    ARTISTRY-1 Proof of Mechanism: Nemvaleukin Preferentially Expands Cytotoxic CD8+ T Cells and NK Cells While Minimally Expanding Tregs Data are from the 6 μg/kg cohort in Part A of ARTISTRY-1. Data are mean + SD (N=12). Vaishampayan et al. Oral Abstract 2500 presented at ASCO 2022. Abbrev: NK: natura

  12. Slide 12: Nemvaleukin's Adverse Event Profile in ARTISTRY-1

    Nemvaleukin’s Adverse Event Profile in ARTISTRY-1 Was Consistent with Our Expectations Based on its Mechanism of Action Dose expansion: monotherapy (Part B) and combination therapy (Part C) Data as of March 27, 2023 Administered on outpatient basis; most frequent AEs were manageable with supportive

  13. Slide 13: ARTISTRY-1: Combination with Pembrolizumab Demonstrated Durable Responses

    ARTISTRY-1: Nemvaleukin Combination Treatment with Pembrolizumab Demonstrated Durable Responses Data cut off Mar 27, 2023 1. DOR data cut off Sept 27, 2023 Abbrev.: BEV: bevacizumab; CBP: carboplatin; CDDP: cisplatin; CR: complete response; DOC: docetaxel; FDA: Food and Drug Administration; GEM: gem

  14. Slide 14: Rationale Underpinning Use of Nemvaleukin in PROC

    Rationale Underpinning Use of Nemvaleukin in PROC Abbrev.: CII: Cancer Immunology, Immunotherapy; CR: complete response; IL-2: interleukin-2; JCO: Journal of Clinical Oncology; ORR: overall response rate; OS: overall survival; PR: partial response; PROC: platinum resistant ovarian cancer In two peer

  15. Slide 15: ARTISTRY-7: Phase 3 Potentially Registrational Study for PROC

    ARTISTRY-7: Phase 3 / Potentially Registrational Study for Platinum-Resistant Ovarian Cancer Pembrolizumab may be administered up to 35 cycles. Investigational Nemvaleukin IV + Pembrolizumab versus Chemotherapy Key eligibility criteria Platinum-resistant/refractory epithelial ovarian, fallopian tube

  16. Slide 16: ARTISTRY-7 Interim Analysis Readout Expected Late Q1 or Early Q2 2025

    ARTISTRY-7 Interim Analysis Readout Expected Late Q1 or Early Q2 2025 Events: ~215 events for planned interim analysis occurred in early Q1 2025 Data Readout: OS IA readout in late Q1 or early Q2 2025 EVENTS AND STATISTICS # of Events: Protocol specified interim analysis (IA) for overall survival (O

  17. Slide 17: ARTISTRY-7 Interim Analysis: Potential Outcomes

    ARTISTRY-7 Interim Analysis (IA): Potential Outcomes 1 2a 2b IA Readout Q1 or early Q2 2025 Next Steps Interim Analysis Meets Bar for Success Study Declared Positive File BLA for PROC in 2025 Decision to Continue to Final Analysis Decision to Terminate Study Interim Analysis Not Statistically Signif

  18. Slide 18: ARTISTRY-1: Durable Monotherapy Responses in Melanoma (Part B)

    Responses per RECIST v1.1 ARTISTRY-1: Nemvaleukin Demonstrated Durable Monotherapy Responses in Melanoma (Part B) Alla,b (n=46) Mucosal (n=6) Best overall response, n (%) CR 0 0 PR 6 (13.0)c 2 (33.3)d ORR, n (%) [95% CI] 6 (13.0) [4.9-26.3]c 2 (33.3) [4.3-77.8]d DOR in weeksd, Mean (SD) Median (rang

  19. Slide 19: ARTISTRY-6 Cohort 2: Phase 2 Trial in Mucosal Melanoma

    Cohort 2 of ARTISTRY-6: Phase 2 - Potentially Registrational Trial of Nemvaleukin in Mucosal Melanoma https://clinicaltrials.gov, NCT04830124 Key eligibility criteria 1 Unresectable and/or metastatic mucosal melanoma Patient has received anti–PD(L)-1 ± anti–CTLA-4 therapy No more than 1 prior system

  20. Slide 20: ARTISTRY-6 Cohort 2: Data Readout Expected in Q2 2025

    ARTISTRY-6 Cohort 2: Data Readout Expected in Q2 2025 Cohort 2 of ARTISTRY-6 study expected to provide the most robust clinical dataset in advanced mucosal melanoma to date Primary analysis will occur when all patients have a minimum follow up of at least 6 months Target response rate: 25% We believ

  21. Slide 21: Exploration of Alternative Dose Administration and Schedule Underway

    Exploration of Alternative Dose Administration and Schedule Underway to Further Optimize Nemvaleukin Profile 5x 2x ARTISTRY-3 Phase 1 Monotherapy - explored 1X and 2X Q3W ARTISTRY-1 Phase 1/2 Monotherapy / Dose Escalation / Expansion / Combination Cohort 2 of ARTISTRY-6 Phase 2 Mucosal Melanoma ARTI

  22. Slide 22: Cohorts 3 and 4 of ARTISTRY-6: Phase 2 Trial in Melanoma

    Cohorts 3 and 4 of ARTISTRY-6: Phase 2 Trial in Melanoma https://clinicaltrials.gov, NCT04830124 Nemvaleukin starting dose will be 30 µg/kg but will allow for de-escalation as necessary per safety data review Key endpoints Primary: ORR per RECIST v1.1 Key secondary: DOR, PFS, DCR, TTR per RECIST v1.

  23. Slide 23: Focused on Near Term Expansion With Vision Towards Next-Generation IO

    Focused on Near Term Expansion With Vision Towards Next-Generation IO Opportunity Source: Clarivate Epidemiology; 1) US and EU Patient Populations. Ba Platinum-Resistant Ovarian Cancer 13K Patients1 FDA Fast Track Designation Potential to be the first immunotherapy option for ovarian patients Mucosa

  24. Slide 24: Section 3: Pipeline Expansion

    Section 3: PIPELINE EXPANSION

  25. Slide 25: IL-18 is a Potent Stimulator of Immunity, but with Key Limitations

    Activates NK cells and antigen-experienced CD8+ T cells Restores activity in dysfunctional T cells Matures dendritic cells (DCs) IL-18R IL-18R MYD88 IL-18 Suppressed activity IL-18R IL-18R IL-18 IL-18BP IL-18BP IL-18BP overexpressed in the TME IL-18BP binds strongly to IL-18 minimizing signaling

  26. Slide 26: Mural Solution: Engineer an IL-18 with Optimized Characteristics

    Mural Solution: Engineer an IL-18 with Optimized Characteristics NK / CD8+ T / DCs IL-18R IL-18R IL-18v IL-18BP IL-18BP-rich TME Engineer an active IL-18 molecule unaffected by IL-18BP presence Engineer an IL-18 with an extended half-life Optimize the IL-18 potency to fit its newly engineered prof

  27. Slide 27: No Binding of Mural Oncology Variants to IL-18BP

    --No Binding-- IL-18 huMOv1 IL-18 huMOv2 No Binding of Mural Oncology Variants to IL-18BP Broad Range of Potency Enhanced Pharmacokinetics Native HuIL-18 tight binding to IL18-BP No binding of MOV to IL18-BP huMOv1/2/3- human Mural Oncology variants IL18BP-resistant, half-life enhanced Preclinical S

  28. Slide 28: Mural's Approach Achieves Intended Half-Life and Pharmacodynamic Effects

    Enhanced Pharmacokinetic Extended Pharmacodynamic muMOv1-mouse Mural Oncology variant IL18BP-resistant, half-life enhanced Mural’s Approach Achieves Intended Half-Life and Associated Pharmacodynamics Effects

  29. Slide 29: Complete Responses and Survival Improvement in IL-18 Mouse Ortholog Variant

    Complete Responses and Survival Improvement Seen in Mural’s IL-18 Mouse Ortholog Variant Agent Dose (mg/kg) % TGI* Day 21 Complete Response Day 50 Probability of Survival Day 50 muMOv1 2.56 86% 2/10 40% muMOv1 5.12 93% 4/10 50% muMOv1 7.68 92% 5/10 50% *%TGI = % tumor growth inhibition, calculated b

  30. Slide 30: Mural Oncology: Building a New Class of Cytokine Therapies

    Mural Oncology: Building a New Class of Cytokine Therapies Abbrev.: CM: cutaneous melanoma; IL-12: interleukin-12; IL-18: interleukin-18; MM: mucosal melanoma; OS: overall survival; PDR: preliminary data readout; PROC: platinum resistant ovarian cancer; RP2D: recommended phase 2 dose; TLR: topline r

  31. Slide 31: Thank You!

    THANK YOU!

  32. Slide 32: Appendix

    APPENDIX

  33. Slide 33: Nemvaleukin Design Details: A New Class of Engineered Fusion Protein

    Nemvaleukin Design Details: A New Class of Engineered Fusion Protein Targeting IL-2 Pathway N C IL-2Ra New locations of N and C termini N C Native component of IL-2 receptor complex directly blocks α component of high affinity IL-2R Minimal alteration to IL-2 sequence maintains IL-2’s structure and

  34. Slide 34: ARTISTRY-3 Cohort 2: Nemvaleukin Increased Immune Activation in Patient Tumors

    ARTISTRY-3 Cohort 2: Nemvaleukin Increased Immune Activation in Patient Tumors Intratumoral Immune Cell Densities Intratumoral Effector:Treg Ratios NK:Treg ratio CD8+:Treg ratio Tot GZB+ CD45RO+ Tot GZB+ CD45RO+ Tot GZB+ CD45RO+ Tot GZB+ CD45RO+ Tot GZB+ CD45RO+ Tot GZB+ CD45RO+ Tot GZB+ CD45RO+ Tot

  35. Slide 35: ARTISTRY-7: Futility Criteria for Monotherapy Arms

    ARTISTRY-7: Futility Criteria for Monotherapy Arms Smaller Single Agent Arms to Assess Contribution of Components Futility criteria for Arm 2: Based on Keynote-100 trial, where single agent pembro was evaluated in 376 patients with PROC with a response rate of 8% Futility in ARTISTRY-7 trial defined

Mural Oncology — Investor Presentation (March 2025) on 6ix